Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.

Award Number: U01EY030406
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 10/17/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2023

Group Awards By:

View Award Description

Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision. - Abstract Sulfur Mustard (SM) has been employed as a chemical weapon, and production and use of SM in unstable regions heightens the risk that this agent could be used in a deliberate terrorist attack against civilians causing mass casualties or against military personnel. The ocular surface is uniquely susceptible to SM resulting in corneal lesions, edema, ulcerations, neovascularization and vision loss. The recommended treatment for ocular SM injury is removal of remaining agent using an eye wash, followed with topical treatments with antibiotics, corticosteroids (anti-inflammatory agents), analgesics and artificial tears. However, a need remains for products that improve healing times, reduce vision loss, and prevent the latent keratitis. Further, there are currently no US Food and Drug Administration approved drugs for SM induced ocular injuries to improve healing and reduce vision loss. Synedgen has developed a class of non-toxic polyglucosamine derivatives with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. Having seen significant healing and anti-inflammatory effects with a particular guanidium modified glycopolymer in a rabbit ocular alkali burn, other derivatives were hypothesized to have potentially better ocular characteristics. This effort proposed three aims to identify and test a treatment for SM ocular injury: 1) synthesize new molecules, 2) down select in in vitro models of inflammation, healing and adhesion and 3) optimize dose in a rabbit model of SM ocular injury. The first two completed aims generated two strong candidate molecules for the SM study proposed in Aim 3. Given successful identification of lead molecules to initiate the final aim of the study, discussions were initiated with the contractor for the proposed SM rabbit study. Because that study was quoted over three years ago, the cost assumptions no longer hold. Although aspects of the study were reduced or eliminated, completion of the study with potentially statistically significant results requires additional funds. This supplemental proposal describes the study design to support the request.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	SYNEDGEN, INC.	1420 N CLAREMONT BLVD	CLAREMONT	CA	91711	LOS ANGELES	USA	Vision Research	000	3	6/7/2023	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $33,733 )
2022	2022	SYNEDGEN, INC.	1420 N CLAREMONT BLVD STE 105D	CLAREMONT	CA	91711	LOS ANGELES	USA	Vision Research	000	3	12/15/2021	SUPPLEMENT FOR EXPANSION	$33,733
														Subtotal = $33,733

Issue Date FY: 2021 ( Subtotal = $319,250 )
2021	2021	SYNEDGEN, INC.	1420 N CLAREMONT BLVD STE 105D	CLAREMONT	CA	91711	LOS ANGELES	USA	Vision Research	000	3	8/2/2021	NON-COMPETING CONTINUATION	$319,250
														Subtotal = $319,250

Issue Date FY: 2020 ( Subtotal = $396,491 )
2020	2020	SYNEDGEN, INC.	1420 N CLAREMONT BLVD STE 105D	CLAREMONT	CA	91711	LOS ANGELES	USA	Vision Research	001	2	8/27/2020	SUPPLEMENT FOR EXPANSION	$74,526
2020	2020	SYNEDGEN, INC.	1420 N CLAREMONT BLVD STE 105D	CLAREMONT	CA	91711	LOS ANGELES	USA	Vision Research	000	2	8/3/2020	NON-COMPETING CONTINUATION	$321,965
														Subtotal = $396,491

Issue Date FY: 2019 ( Subtotal = $329,155 )
2019	2019	SYNEDGEN, INC.	1420 N CLAREMONT BLVD STE 105D	CLAREMONT	CA	91711	LOS ANGELES	USA	Vision Research	000	1	9/17/2019	NEW	$329,155
														Subtotal = $329,155

Grand Total All Awards = $1,078,629

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.

Award Number: U01EY030406

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 10/17/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer